Status message

Not the entire site translated, but only to "Journal"

Cariprazine: Neuroendocrine and Metabolic Aspects of Tolerance in Patients with Mental Disorders

The review article analyzes the data of scientific publications concerning the psychoendocrinological and metabolic problems of therapy with the modern third generation antipsychotic, cariprazine, in patients with schizophrenia and bipolar disorder. In a comparative aspect, data on the incidence and severity of individual anthropometric and biochemical indicators of neuroendocrine dysfunctions are presented. The data of comparative studies on the effect of individual antipsychotics in comparison with cariprazine, as well as different doses of the drug on the levels of prolactin, high density lipoproteins (HDL) and low density lipoproteins (LDL), glucose, triglycerides, as well as changes in body weight of patients with mental disorders, in particular, taking into account the age factor. The advantages of cariprazine in terms of safety and tolerability in relation to hyperprolactinemia (HP) and metabolic disorders are shown.

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.


1. Gorobets L.N., Litvinov A.V., Polyakovskaya T.P. Psikhoendokrinologicheskie aspekty perenosimosti prolongirovannykh form antipsikhotikov u bol'nykh s rasstroistvami shizofrenicheskogo spektra // Psikhiatriya i psikhofarmakoterapiya. – 2013. – T. 15, № 4. – S. 12–19.
2. Mosolov S.N. Antipsikhoticheskaya farmakoterapiya shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya meditsina – klinicheskoi praktike / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – S. 11–60.
3. Gorobets L.N., Mazo G.E Neiroendokrinnye disfunktsii pri ispol'zovanii psikhofarmakoterapii: klinika, diagnostika, faktory riska i korrektsiya // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 2014. – T. 114, № 10. – S. 122–130.
4. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. – 4rd ed. – Cambridge: Cambridge University Press, 2013.
5. Kapur S., Zipursky R., Jones C. et al. Relationship between dopamine D2 occupancy, clinical response and side effects: a double - blind PET study of first - episode schizophrenia // Am J Psychiatry. – 2000. Vol. 157 (4). – P. 514–520.
6. Kapur S., Langlois X., Vinkern P. et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats // J Pharmacol Exp Ther. – 2002. – Vol. 302 (3). – P. 1129–1134.
7. Choi Y.K., Adham N., Kiss B., Gyertyán I., Tarazi F.I. Long-term effects of cariprazine exposure on dopamine receptor subtypes // CNS Spectrums. – 2014. – Vol. 19. – P. 268–277.
8. Newcomer J.W., Haupt D.W. The metabolic effects of antipsychotic medications // Can J Psychiatry. – 2006. –Vol. 51. – P. 480–491.
9. Correll C.U., Jain R., Meyer J.M., Periclou A., Carrothers T., Barabássy Á., Patel M., Earley W. Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation // Neuropsychiatr Dis Treat. – 2019. – Vol. 15. – P. 2537–2550.
10. Shmukler A.B. Kariprazin – antipsikhotik s novymi unikal'nymi potentsial'nymi vozmozhnostyami dlya lecheniya shizofrenii i affektivnykh rasstroistv // Sotsial'naya i klinicheskaya psikhiatriya. – 2014. – T. 24, № 2. – C. 72–75.
11. Medvedev V.E. Kariprazin – novyi antipsikhotik dlya lecheniya shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2019. – № 2yu – S. 22–29. DOI: 10.21265/PSIPH2019.59.55.004
12. Bykov Yu.V., Bekker R.A., Morozov P.V. Effektivnost' kariprazina v lechenii shizofrenii, osobenno s preobladaniem negativnoi simptomatiki // Psikhiatriya i psikhofarmakoterapiya. – 2018. – T. 20, № 5. S. 27–37.
13. Durgam S., Starace A., Li D. et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial // Schizophr Res. –2014. – № 152. – S. 450–457.
14. Citrome L., Durgam S., Lu K., Ferguson P., Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia // J Clin Psychiatry. – 2016. – № 77. – S. 109–115.
15. Durgam S., Litman R., Papadakis K., Li D., Németh G., Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial // Int Clin Psychopharmacol. – 2016. – № 31. – S. 61–68.
16. Earley W., Durgam S., Lu K., Laszlovszky I., Debelle M., Kane J.M. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies // Int Clin Psychopharmacol. – 2017. – № 32. – S. 319–328.
17. Caccia S. Invernizzi R.W., Nobili A., Pasina I. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia // Therapeutics and Clinical Risk Management. – 2013. – Vol. 9. – P. 319–328.
18. Kane J.M., Zukin S., Wang Y., Lu K., Ruth A., Nagy K., Laszlovszky I., Durgam S. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial // J Clin Psychopharmacol. – 2015. – Vol. 35. – P. 367–373.
19. Durgam S., Earley W., Li R., Li D., Lu K., Laszlovszky I., Fleischhacker W.W., Nasrallah H.A. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial // Schizophr Res. – 2016. – № 176. – S. 264–271.
20. Durgam S., Greenberg W.M., Li D., Lu K., Laszlovszky I., Németh G., Migliore R., Volk S. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, open-label extension study // Psychopharmacology. – 2017. – Vol 234. – P. 199–209.
21. Cutler A., Durgam S., Wang Y., Migliore R., Lu K., Laszlovszky I., Németh G. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: Results from a 1-year open-label study // CNS Spectrums. – 2018. – Vol. 23. – P. 39–50.
22. Nasrallah H., Earley W., Cutler A., Wang Y., Lu K., Laszlovszky I., Németh G., Durgam S. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis // BMC Psychiatry. – 2017. – Vol. 17. – P. 305.
23. Assessment report: Reagila / International non-proprietary name: cariprazine. European Medicines Agency, 2017. – Available at: (accessed 12.06.2020).
24. Calabrese J.R., Keck P.E., Starace A., Lu K., Ruth A., Laszlovszky I., Németh G., Durgam S. Efficacy and safety of low- and high-dose cariprazine in patients with acute and mixed mania associated with bipolar I disorder // J Clin Psychiatry. – 2015. – Vol. 76. – P. 284–292.
25. Durgam S., Starace A., Li D., Migliore R., Ruth A., Németh G., Laszlovszky I. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: A phase II trial // Bipolar Disord. – 2015. – Vol. 17. – P. 63–75.
26. Earley W., Durgam S., Lu K., Debelle M., Laszlovszky I., Vieta E., Yatham L.N. Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies // J Affect Disord. – 2017. – Vol. 215. – P. 205–212.
27. Ketter T.A., Sachs G.S., Durgam S., Lu K., Starace A., Laszlovszky I., Németh G. The safety and tolerability of cariprazine in patients with bipolar I disorder: A 16-week open-label study // J Affect Disord. – 2018. – Vol. 225. – P. 350–356.
28. Fava M., Durgam S., Earley W., Lu K., Hayes R., Laszlovszky I., Németh G. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial // Int Clin Psychopharmacol. – 2018. – Vol. 33. – P. 312–321.
29. Szatmári B., Barabássy Á., Harsányi .J, Laszlovszky I., Sebe B., Gál M., Shiragami K., Németh G. Cariprazine safety in adolescents and the elderly: Analyses of clinical study data // Front Psychiatry. – 2020. – Vol. 11 (article 61). – P. 1–11.